Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kwality PharmaceuticalsNSE:KPL +5.15%60 EV-to-EBIT is 33.15 as of Aug. 21, 2026, which is 72% above its 10-year median of 19.31. GuruFocus rates NSE:KPL with a GF Score™ of 60/100 and a GF Value™ of ₹1,332.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Kwality Pharmaceuticals ranks worse than 77.54% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kwality Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was ₹0 Mil.
Kwality Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,173 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kwality Pharmaceuticals EV-to-EBIT Related Terms
Kwality Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kwality Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kwality Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kwality Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kwality Pharmaceuticals's EV-to-EBIT falls into.
Kwality Pharmaceuticals's current Enterprise Value is ₹38,891 Mil.
Kwality Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,173 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kwality Pharmaceuticals (NSE:KPL) has a EV-to-EBIT of 33.15 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kwality Pharmaceuticals and its competitors. This is 72% above median its historical median of 19.31. Over the past decade, Kwality Pharmaceuticals' EV-to-EBIT has ranged from 2.30 to 78.23. According to the industry distribution chart, Kwality Pharmaceuticals ranks #535 out of 690 companies in the Drug Manufacturers industry, placing it in the top 77.5%.
Is Kwality Pharmaceuticals' EV-to-EBIT too high?
Kwality Pharmaceuticals' current EV-to-EBIT of 33.15 is 72% above median its 10-year median of 19.31. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 78.23. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Kwality Pharmaceuticals' value of 33.15 is 119.3% above this industry median. Based on the distribution chart, Kwality Pharmaceuticals ranks #535 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kwality Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' EV-to-EBIT compare to ?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #535 out of 690 companies for EV-to-EBIT. This places Kwality Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.12. Kwality Pharmaceuticals' value of 33.15 is 119.3% above this benchmark. Historically, Kwality Pharmaceuticals' own EV-to-EBIT has ranged from 2.30 to 78.23 over the past decade. While the company's 10-year median is 19.31 vs. the industry median of 15.12, Kwality Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kwality Pharmaceuticals's current EV-to-EBIT of 33.15 is 119.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kwality Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kwality Pharmaceuticals's current EV-to-EBIT is 33.15, which is 72% above median its own 10-year median of 19.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (NSE:KPL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,332.01, compared to a current price of ₹3,630.30 — trading 172.5% above its estimated fair value. The current EV-to-EBIT is 33.15, which is 72% above median its 10-year median of 19.31 and 119.3% above the Drug Manufacturers industry median of 15.12. Kwality Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kwality Pharmaceuticals (NSE:KPL), the current EV-to-EBIT is 33.15 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (NSE:KPL) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹3,630.30 is trading 172.5% above its estimated GF Value™ of ₹1,332.01.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:KPL:
EV-to-EBIT: 33.15 (72% above median its 10-year median of 19.31)
GF Value™: ₹1,332.01 vs. price of ₹3,630.30 (172.5% above fair value)
Industry Position: 119.3% above the Drug Manufacturers median (#535 of 690)
No single metric tells the full story. See the NSE:KPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
60GF Score
Get the complete analysis for NSE:KPL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KPL has been successfully added to your 
